The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study

Chuanwei Xin, Zhongni Xia, Gonghua Li Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, People’s Republic of ChinaCorrespondence: Gonghua LiDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Gucui Road, Hangzhou, Zhejiang Province, People’s Republic of ChinaTel +86 571 8997 2240Email xyaoshi9@163.comBackground: The challenge of drug resistance to carbapenems is of international concern with leading to increased hospital lengths of stay, costs, and mortality rates. How to get rid of the vicious cycle of drug resistance, new drugs, and re-resistance, and even the emergence of all-drug-resistant bacteria that humans cannot cope with, are the major challenges we face. To date, data about pharmaceutical interventions on the use of carbapenems are currently limited.Patients and methods: A retrospective cohort study was conducted to compare pre- and post-intervention in Tongde Hospital of Zhejiang Province. Pharmaceutical interventions were performed in the post-intervention group, including real time monitoring of medication orders, educative group activities, and making interventions to physicians. Intervention acceptance and outcomes, including the length of hospital stay, readmission rates, 30-day mortality, and utilization of carbapenems, which was evaluated by the daily defined doses (DDDs), the days of therapy (DOTs), and the cost of carbapenems, were reviewed.Results: During the study, 593 interventions were provided by clinical pharmacists with an average acceptance rate of 82.79%. Compared with the pre-intervention group, prescriptions of carbapenems for pathogen-directed therapy were improved significantly in the post-intervention group (59.27% vs 21.74%, p=0.022). The DDDs decreased from 281.96 to 174.28 and DOTs decreased from 9.19 to 5.18 after pharmaceutical intervention, and the pharmaceutical interventions had significantly lower mean total cost of carbapenems ($13,828.8 vs $8137.1, p=0.004) and length of hospital stay (9.3±1.5 vs 15.9±2.2, p=0.014). There was a significant reduction in 30-day mortality in the post-intervention group (9.46% vs 17.86%, p=0.013) while there were no differences found in the 30-day readmission (20.19% vs 20.66%, p=0.99).Conclusion: Implementation of pharmaceutical interventions in our hospital successfully improved the appropriateness of carbapenem prescribing overall, and reduced the DDDs, DOTs, length of hospital day, and cost of carbapenems.Keywords: carbapenems, pharmaceutical interventions, readmission rates, daily defined doses, days of therapy